An Infographic Look At Trends In Korean Gene And Stem Cell Therapies
Executive Summary
South Korea has opened a new era with the recent granting of approval to the country's first gene therapy, for Kolon Life Science's osteoarthritis drug Invossa. (Also see "First Approval For Kolon's Invossa But No Disease-Modifying Status" - Scrip, 14 Jul, 2017.) Scrip takes a graphical look at the current state of the country's wider gene and stem cell therapy sector, one of the key biotech areas the government is nurturing.
You may also be interested in...
First Approval For Kolon's Invossa But No Disease-Modifying Status
Kolon Life Science's Invossa gets regulatory approval in South Korea as the world's first allogeneic cell-mediated gene therapy for degenerative osteoarthritis, but misses out on disease-modifying status, although the company hopes a large-scale Phase III study can rectify this in the US.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.